High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer

Breast cancer is the most common malignancy affecting women, but the heterogeneity of the condition is a significant obstacle to effective treatment. Triple negative breast cancers (TNBCs) do not express HER2 or the receptors for estrogen or progesterone, and so often have a poor prognosis. Tumor-infiltrating T cells have been well-characterized in TNBC, and increased numbers are associated with better outcomes; however, the potential roles of B cells and plasma cells have been large. Here, we conducted a retrospective correlative study on the expression of B cell/plasma cell-related genes, and the abundance and localization of B cells and plasma cells within TNBCs, and clinical outcome. We analyzed 269 TNBC samples and used immunohistochemistry to quantify tumor-infiltrating B cells and plasma cells, coupled with NanoString measurement of expression of immunoglobulin metagenes. Multivariate analysis revealed that patients bearing TNBCs with above-median densities of CD38+ plasma cells had significantly better disease-free survival (DFS) (HR = 0.44; 95% CI 0.26–0.77; p = 0.004) but not overall survival (OS), after adjusting for the effects of known prognostic factors. In contrast, TNBCs with higher immunoglobulin gene expression exhibited improved prognosis (OS p = 0.029 and DFS p = 0.005). The presence of B cells and plasma cells was positively correlated (p < 0.0001, R = 0.558), while immunoglobulin gene IGKC, IGHM, and IGHG1 mRNA expression correlated specifically with the density of CD38+ plasma cells (IGKC p < 0.0001, R = 0.647; IGHM p < 0.0001, R = 0.580; IGHG1 p < 0.0001, R = 0.655). Interestingly, after adjusting the multivariate analysis for the effect of intratumoral CD38+ plasma cell density, the expression levels of all three genes lost significant prognostic value, suggesting a biologically important role of plasma cells. Last but not least, the addition of intratumoral CD38+ plasma cell density to clinicopathological features significantly increased the prognostic value for both DFS (ΔLRχ2 = 17.28, p = 1.71E−08) and OS (ΔLRχ2 = 10.03, p = 6.32E−08), compared to clinicopathological features alone. The best combination was achieved by integrating intratumoral CD38+ plasma cell density and IGHG1 which conferred the best added prognostic value for DFS (ΔLRχ2 = 27.38, p = 5.22E−10) and OS (ΔLRχ2 = 21.29, p = 1.03E−08). Our results demonstrate that the role of plasma cells in TNBC warrants further study to elucidate the relationship between their infiltration of tumors and disease recurrence.

[1]  I. Ellis,et al.  Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ , 2017, Histopathology.

[2]  P. Tan,et al.  Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.

[3]  C. Sotiriou,et al.  An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers , 2016, Breast Cancer Research.

[4]  K. Jirström,et al.  Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. , 2016, Journal of gastrointestinal oncology.

[5]  J. Rosenblatt,et al.  B cell regulation of the anti-tumor response and role in carcinogenesis , 2016, Journal of Immunotherapy for Cancer.

[6]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[7]  P. Fu,et al.  Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival. , 2016, Pathology, research and practice.

[8]  I. Reis,et al.  HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline , 2016, Breast Cancer Research and Treatment.

[9]  B. Nelson,et al.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.

[10]  M. Garnelo,et al.  Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma , 2015, Gut.

[11]  Noriaki Ohuchi,et al.  Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study , 2015, Breast Cancer Research.

[12]  E. Levy,et al.  Editorial: “Cancer Immunotherapy: Lights and Shadows” , 2015, Front. Immunol..

[13]  M. Mathieu,et al.  Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Tan,et al.  Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.

[15]  J. Mordoh,et al.  Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some , 2015, Front. Immunol..

[16]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Tan,et al.  Role of inflammatory infiltrates in triple negative breast cancer , 2015, Journal of Clinical Pathology.

[18]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[19]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Ping Sun,et al.  Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. , 2015, JAMA.

[21]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[22]  Fan Lin,et al.  Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. , 2014, Archives of pathology & laboratory medicine.

[23]  L. Miller,et al.  Dual roles for immune metagenes in breast cancer prognosis and therapy prediction , 2014, Genome Medicine.

[24]  D. Rimm,et al.  Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Clinical Cancer Research.

[25]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jiang Gu,et al.  Immunoglobulin G Expression in Lung Cancer and Its Effects on Metastasis , 2014, PloS one.

[27]  M. Hallek,et al.  Characterization of tumor-associated B-cell subsets in patients with colorectal cancer , 2014, Oncotarget.

[28]  P. Validire,et al.  Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. , 2014, American journal of respiratory and critical care medicine.

[29]  Puay Hoon Tan,et al.  Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer , 2014, Modern Pathology.

[30]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[31]  J. Gu,et al.  Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species , 2013, Cell Death and Disease.

[32]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. McMillan,et al.  The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer , 2013, British Journal of Cancer.

[34]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[35]  P. Tan,et al.  Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor–product relationship , 2013, Journal of Clinical Pathology.

[36]  Pierre Hainaut,et al.  Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. , 2013, Current opinion in oncology.

[37]  Marcus Schmidt,et al.  IGKC and Prognosis in Breast Cancer–Letter , 2012, Clinical Cancer Research.

[38]  B. Nelson,et al.  Tumor-infiltrating B cells and T cells , 2012, Oncoimmunology.

[39]  Marcus Schmidt,et al.  Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors , 2012, Oncoimmunology.

[40]  Marcus Schmidt,et al.  Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer , 2012, PloS one.

[41]  M. Sales,et al.  Immunoglobulin G from Breast Cancer Patients Regulates MCF-7 Cells Migration and MMP-9 Activity by Stimulating Muscarinic Acetylcholine Receptors , 2012, Journal of Clinical Immunology.

[42]  K. Öberg.  Implications for Clinical Practice and Trial Design , 2012 .

[43]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[44]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[45]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[46]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[47]  T. Whiteside,et al.  For Breast Cancer Prognosis, Immunoglobulin Kappa Chain Surfaces to the Top , 2012, Clinical Cancer Research.

[48]  L. Holmberg,et al.  A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors , 2012, Clinical Cancer Research.

[49]  F. Marincola,et al.  The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.

[50]  L. Pusztai,et al.  Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes , 2012, Breast Cancer Research and Treatment.

[51]  T. Shibata,et al.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[52]  A. Levine,et al.  Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect , 2011, Proceedings of the National Academy of Sciences.

[53]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[54]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[55]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[56]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[57]  A. Jara-Lazaro,et al.  Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer , 2010, Modern Pathology.

[58]  K. Mankad,et al.  Is it safe practice not to biopsy fibroadenomas in women under 30? , 2009, Breast Cancer Research.

[59]  Jan G Hengstler,et al.  Coordinates in the universe of node-negative breast cancer revisited. , 2009, Cancer research.

[60]  Louis M Weiner,et al.  Monoclonal antibodies for cancer immunotherapy , 2009, The Lancet.

[61]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[62]  L. Truong,et al.  Undifferentiated tumor: true identity by immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.

[63]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[64]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[65]  Thomas F. Tedder,et al.  Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.

[66]  L. Truong,et al.  True Identity by Immunohistochemistry , 2008 .

[67]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[68]  G. Collins.  The next generation. , 2006, Scientific American.

[69]  S. Saga,et al.  Class distribution of immunoglobulin-containing plasma cells in the stroma of medullary carcinoma of breast , 2005, Breast Cancer Research and Treatment.

[70]  G. Pinkus,et al.  CD138 (Syndecan-1), a Plasma Cell Marker , 2004 .

[71]  E. Hersh,et al.  Naturally occurring B-cell responses to breast cancer , 2003, Cancer Immunology, Immunotherapy.

[72]  P. Chu,et al.  Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. , 2003, American journal of clinical pathology.

[73]  B. Smoller,et al.  The Level of Syndecan-1 Expression is a Distinguishing Feature in Behavior between Keratoacanthoma and Invasive Cutaneous Squamous Cell Carcinoma , 2002, Modern Pathology.

[74]  S. Ikehara,et al.  Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs1 , 2001, The Journal of Immunology.

[75]  S. Eccles.  Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? , 2000, Breast Cancer Research.

[76]  G. Nicolardi,et al.  Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. , 1999, Cancer letters.

[77]  L. Happerfield,et al.  Angiogenesis and inflammation in ductal carcinoma in situ of the breast , 1997, The Journal of pathology.

[78]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[79]  G. Mackie.  Evidence for a precursor-product relationship in the biosynthesis of ribosomal protein S20. , 1977, Biochemistry.